ClinicalTrials.gg
CompletedNCT03619681Updated Mar 12, 2024

Trial of KN026 in Patients With HER2-positive Advanced Malignant Breast Cancer and Gastric Cancer

A Phase 1 interventional study of KN026 in Breast Cancer and Gastric Cancer, sponsored by Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-03-12.

Sponsored by Jiangsu Alphamab Biopharmaceuticals Co., Ltd (part of Alphamab Oncology) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
63
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,930 studies in Breast Neoplasms with a site in China — 868 open to participants now, 1,065 under way, 210 of them phase 3. Breast Neoplasms · China.

Enrollment
1,049th of 1,520
63 · median 120
Started
2018
with 71 others
Phase 1
171 of 1,930
61 open now
Registered
434th of 1,930
by date

Among the 1,930 studies in Breast Neoplasms with a site in China, this one is the 1,049th largest by enrollment of the 1,520 interventional ones that give a count, is one of 72 that started in 2018, is one of 171 in phase 1, and was the 434th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

868 of the 1,930 studies in Breast Neoplasms with a site in China are open now. Recruiting first, the newest first:

863 more — sign in →

All 868 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,930 studies in Breast Neoplasms with a site in China, or all of them as a file.
02

Study summary

This is a first-in-human (FIH), open-label, phase 1 dose-escalation study of KN026 in subjects with HER2 positive advanced breast and Gastric Cancer. The standard "3 + 3" design was used for dose escalation. There are 5 proposed dose levels which are 5, 10, 15, 20 and 30 mg/kg, but dosing interval may be adjusted during the study (such as QW, OR Q2W, OR Q3W) based on emerging data from this trial and/or from phase 1 trial of KN026 in other country. Dose escalation will continue until the maximum tolerated dose (MTD) is reached or if MTD is not found, dose escalation will continue until the MAD of 20 mg / kg is reached. Dose expansion will carried out in 20 mg/kg Q2W and 30 mg/kg Q3W.

03

Conditions studied

  • Breast Cancer
  • Gastric Cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subject >= 18 years and =\<75 years.
  • or cytologically confirmed, locally advanced unresectable or breast cancer or gastric cancer.
  • score 0 or 1.
  • >3 months.
  • According to the definition of RECIST1.1, the patient has at least one .
  • Adequate organ function prior to start treatment with KN026.
  • Able to understand, voluntarily participate and willing to sign the ICF.
  • Subjects (women of and males with fertile female partner) must be willing to use viable method.

Exclusion criteria

Exclusion Criteria:

  • Accepted any other anti-tumor drug therapies within 4 weeks before fist dose.
  • Accepted radiotherapy within 4 weeks before enrollment(Subjects are eligible, which accepted palliative therapies within 2 weeks before the first dose of KN026 for osseous and all the AEs recovered).
  • An anthracyclines antibiotic treatment, such as doxorubicin (Adriamycin) was received exceeding 300 mg/m² within 90 days before first KN026 dosing, or other equivalent dose antharcyclines.
  • Subjects are eligible with clinically controlled and stable neurologic function >= 4 weeks, which is no evidence of CNS disease progression; Subjects with spinal cord compression and cancerous meningitis are not eligible.
  • Pregnant or nursing females;or intend pregnancy within this study period or within 6 monthes after the end of this study.
  • Has not recovered (ie, >Grade 1) from AEs except alopecia and anemia.
  • History of immunodeficiency, including positive or other acquired, congenital immunodeficiency disease, or a history of organ transplantation.
  • Severe chronic and active infection, need to system antibiosis/antiviral treatment.
  • Cavity effusion (pleural effusion, ascites, pericardial effusion, etc.) are not well controlled, and need locally treatment or repeated drainage. -
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
63 participants (actual)

Study arms

  • Experimental
    KN026

    Drug: KN026

Interventions

  • DrugKN026

    Patient will be intravenously administrated with one dose of KN026. dosing interval may be adjusted during the study based on emerging data from this trial and/or from other trial.

06

What researchers measure

Primary outcomes

  1. The proportion of patients experiencing dose limiting toxicities.

    Time frame: From screening to up to 28 days

Secondary outcomes

  1. Percentage of participants with adverse events (AEs), serious adverse events (SAEs) and AEs of special interest.

    Time frame: From screening to up to 112 days

  2. Percentage of participants who experience laboratory abnormalities and/or adverse events as defined by CTCAE that are related to treatment

    Time frame: From screening to up to 112 days

  3. Maximum observed serum concentration (Cmax) of KN026.

    Time frame: Throughout the duration of the study; up to 84 days

  4. Time of Maximum observed serum concentration (Tmax) of KN026.

    Time frame: Throughout the duration of the study; up to 84 days

  5. Adjusted geometric means of area under the serum concentration-time curve from time zero to the time of last quantifiable concentration (AUC(0-T)) for KN026.

    Time frame: Throughout the duration of the study; up to 84 days

  6. Serum Half-life (T-HALF) of KN026.

    Time frame: Throughout the duration of the study; up to 84 days.

  7. Serum clearance (CL) of KN026.

    Time frame: Throughout the duration of the study; up to 84 days

  8. Volume of distribution at steady state (VSS) of KN026.

    Time frame: Throughout the duration of the study; up to 84 days

  9. Frequency and titer of anti-KN026 antibody.

    Time frame: Throughout the duration of the study; up to 2 years.

  10. The proportion of patients with an objective response (partial response or complete response) as defined by RECIST 1.1 criteria.

    Time frame: Throughout the duration of the study; up to 2 years.

  11. Progression free survival according to RECIST 1.1 criteria.

    Time frame: Throughout the duration of the study; up to 2 years.

07

Study locations

1 site
  • Fudan University Shanghai Cancer Hospital
    Shanghai, 200000, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2018 to primary completion in Jun 2022, 45 months.

Of 389 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's 45 months is above that.

Counting every sponsor, half of 761 studies reached it within 44 months; a quarter within 25 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2018
First posted
Aug 8, 2018
StartActual
Sep 17, 2018
Primary completionActual
Jun 30, 2022
CompletionActual
Aug 26, 2022
Last update
Mar 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03619681
Responsible party
Sponsor
First posted
Aug 8, 2018
Start date
Sep 17, 2018
Primary completion
Jun 30, 2022
Completion
Aug 26, 2022
Last update
Mar 12, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anbenitamab

Start the discussion